BDBM391334 Trans 2-(1-(3-((4- ((difluoromethyl)sulfonyl) phenyl)amino)-4-oxo-4,5- dihydro-1H-pyrazolo [4,3-c]pyridin-1- yl)-4-(3-fluoroazetidin-1- yl)cyclohexyl)acetonitrile::US9957264, Example 18-28

SMILES: FC(F)S(=O)(=O)c1ccc(Nc2nn(c3cc[nH]c(=O)c23)[C@@]2(CC#N)CC[C@@H](CC2)N2CC(F)C2)cc1

InChI Key:

Data: 2 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 391334   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Tyrosine-protein kinase JAK2 (Homo sapiens (Human))	BDBM391334 (Trans 2-(1-(3-((4- ((difluoromethyl)sulfonyl) phen...) Show SMILES FC(F)S(=O)(=O)c1ccc(Nc2nn(c3cc[nH]c(=O)c23)[C@@]2(CC#N)CC[C@@H](CC2)N2CC(F)C2)cc1 |r,wU:27.32,wD:21.22,(-6.74,-6.02,;-6.27,-4.55,;-7.3,-3.41,;-4.76,-4.23,;-5.08,-2.73,;-4.44,-5.74,;-3.25,-3.91,;-2.22,-5.06,;-.72,-4.74,;-.24,-3.27,;1.27,-2.95,;1.74,-1.49,;.84,-.24,;1.74,1,;3.21,.53,;4.54,1.3,;5.87,.53,;5.87,-1.01,;4.54,-1.78,;4.54,-3.32,;3.21,-1.01,;1.27,2.47,;2.79,2.68,;3.37,4.11,;3.94,5.54,;1.32,4.01,;.01,4.82,;-1.35,4.1,;-1.4,2.56,;-.09,1.74,;-2.65,4.92,;-4.15,4.57,;-4.5,6.07,;-5.81,6.89,;-3,6.42,;-1.27,-2.13,;-2.78,-2.45,)| Show InChI	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.110	n/a	n/a	n/a	n/a	n/a	n/a
GSK					Assay Description The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...				Bioorg Med Chem Lett 19: 360-4 (2009) BindingDB Entry DOI: 10.7270/Q2KH0QN8
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK1 (Homo sapiens (Human))	BDBM391334 (Trans 2-(1-(3-((4- ((difluoromethyl)sulfonyl) phen...) Show SMILES FC(F)S(=O)(=O)c1ccc(Nc2nn(c3cc[nH]c(=O)c23)[C@@]2(CC#N)CC[C@@H](CC2)N2CC(F)C2)cc1 |r,wU:27.32,wD:21.22,(-6.74,-6.02,;-6.27,-4.55,;-7.3,-3.41,;-4.76,-4.23,;-5.08,-2.73,;-4.44,-5.74,;-3.25,-3.91,;-2.22,-5.06,;-.72,-4.74,;-.24,-3.27,;1.27,-2.95,;1.74,-1.49,;.84,-.24,;1.74,1,;3.21,.53,;4.54,1.3,;5.87,.53,;5.87,-1.01,;4.54,-1.78,;4.54,-3.32,;3.21,-1.01,;1.27,2.47,;2.79,2.68,;3.37,4.11,;3.94,5.54,;1.32,4.01,;.01,4.82,;-1.35,4.1,;-1.4,2.56,;-.09,1.74,;-2.65,4.92,;-4.15,4.57,;-4.5,6.07,;-5.81,6.89,;-3,6.42,;-1.27,-2.13,;-2.78,-2.45,)| Show InChI	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0500	n/a	n/a	n/a	n/a	n/a	n/a
GSK					Assay Description The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...				Bioorg Med Chem Lett 19: 360-4 (2009) BindingDB Entry DOI: 10.7270/Q2KH0QN8
					More data for this Ligand-Target Pair